Segall Bryant & Hamill LLC reduced its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 15.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,326 shares of the biotechnology company's stock after selling 18,008 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.20% of Vericel worth $5,344,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Arcadia Investment Management Corp MI purchased a new stake in shares of Vericel in the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC raised its position in Vericel by 511.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after buying an additional 1,058 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Vericel by 826.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after buying an additional 2,240 shares during the last quarter. Quantbot Technologies LP bought a new position in Vericel during the 3rd quarter valued at $146,000. Finally, KBC Group NV boosted its holdings in Vericel by 82.5% during the 4th quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 1,224 shares during the last quarter.
Insider Buying and Selling at Vericel
In other Vericel news, CEO Dominick Colangelo sold 26,592 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares of the company's stock, valued at $11,902,662.66. The trade was a 9.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Siegal sold 3,908 shares of the firm's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the transaction, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 over the last three months. 5.20% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on VCEL. Stephens reissued an "overweight" rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Truist Financial reaffirmed a "buy" rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Canaccord Genuity Group raised their target price on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Vericel has an average rating of "Moderate Buy" and an average price target of $62.29.
Read Our Latest Analysis on Vericel
Vericel Stock Performance
NASDAQ:VCEL traded down $1.54 during trading hours on Tuesday, reaching $43.08. The stock had a trading volume of 421,168 shares, compared to its average volume of 378,012. The stock has a market cap of $2.16 billion, a P/E ratio of 718.12 and a beta of 1.78. The stock has a 50 day simple moving average of $52.61 and a 200 day simple moving average of $51.77. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00.
Vericel Profile
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Further Reading
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
